CompletedPhase 2NCT00217620
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Margaret von Mehren, MDFox Chase Cancer Center
- Intervention
- sorafenib(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2012
Study locations (30)
- Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
- Peninsula Medical Center, Burlingame, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Marin Cancer Institute at Marin General Hospital, Greenbrae, California, United States
- Sutter Health - Western Division Cancer Research Group, Greenbrae, California, United States
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- Kaiser Permanente Medical Office -Vandever Medical Office, San Diego, California, United States
- California Pacific Medical Center - California Campus, San Francisco, California, United States
- Sutter Solano Medical Center, Vallejo, California, United States
- Front Range Cancer Specialists, Fort Collins, Colorado, United States
- Poudre Valley Hospital, Fort Collins, Colorado, United States
- M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00217620 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive